InflaRx is a clinical-stage biopharmaceutical company focused on applying its anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. C5a is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. Co.'s primary product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in various clinical settings. Co. develops vilobelimab for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The IFRX average annual return since 2017 is shown above.
The Average Annual Return on the IFRX average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IFRX average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IFRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free IFRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
